Comparison of Efficacy and Safety of Anti-Programmed Cell Death-1 Antibody Plus Lenvatinib and Chemotherapy as First-Line Therapy for Patients with Stage IV Gallbladder Cancer: A Real-World Study in a Chinese Population

Background: The present study aimed to evaluate and compare the efficacy and safety of anti-programmed cell death protein 1 (anti-PD-1) antibody plus lenvatinib (tyrosine kinase inhibitor) therapy and chemotherapy as the first-line treatment to unresectable stage IV gallbladder cancer (GBC). Methods...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Tiantian, Pu, Changsheng, Wang, Qiang, Zhang, Keming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669544/
https://www.ncbi.nlm.nih.gov/pubmed/38001934
http://dx.doi.org/10.3390/biomedicines11112933

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669544/
https://www.ncbi.nlm.nih.gov/pubmed/38001934
http://dx.doi.org/10.3390/biomedicines11112933

Ejemplares similares